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We evaluated the expression patterns of proapoptotic BAX, antiapoptotic Bcl-2 and p53, the proposed upstream effector of these
molecules, as potential prognostic markers in UICC stage III colon cancer by immunohistochemical staining. To identify high-
frequency microsatellite instability (MSIþ) individuals, we performed single-strand conformation polymorphism-based analysis for
BAT26. A total of 188 patients who had received 5-fluorouracil (5-FU)-based adjuvant chemotherapy (5-FU/folinic acid or 5-FU/
levamisole) were enrolled. Median follow-up was 84.5 months. We found that BAX, Bcl-2 and p53 protein expressions were high or
positive in 59, 70 and 50% of 188 cases, respectively. MSIþ tumours were detected in 9% of 174 evaluable patients. BAX or Bcl-2
was correlated with a higher degree of differentiation or left-sided tumours (P¼0.01 or P¼0.03, respectively); MSI was correlated
with right-sided tumours (Po0.0001). In contrast to p53, Bcl-2, or MSI, low BAX, advanced pN category, low grade of differentiation
and treatment with 5-FU/levamisole were univariately associated with poorer disease-free survival (DFS) (P¼0.0005, P¼0.001,
P¼0.005 and P¼0.01, respectively) and poorer overall survival (OS) (P¼0.002, P¼0.0001, P¼0.003 and P¼0.02, respectively).
Besides pN category and treatment arm, BAX was an independent variable related to both OS and DFS (P¼0.003 and P¼0.001,
respectively). In both univariate and multivariate analysis, the p53 /BAX high in comparison with the p53þ/BAX high subset
conferred a significantly improved DFS (P¼0.03 and P¼0.03, respectively) as well as a marginally improved OS (P¼0.07 and
P¼0.08, respectively). BAX protein expression may be of central significance for clinical outcome to 5-FU-based adjuvant
chemotherapy in stage III colon cancer, and bivariate analysis of p53/BAX possibly may provide further prognostic evidence.
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In patients with colon cancer, the extent of tumour stage, defined
by the depth of invasion, involvement of lymph nodes and
metastatic spread to distant organs, still confers the most useful
prognostic information. However, while stages I and IV (UICC)
have a uniform favourable and dismal prognosis, respectively, the
5-year survival rates reported for patients with stage II colorectal
cancer vary between 62 and 70%, and between 27 and 60% for
patients with stage III disease (Macdonald and Astrow, 2001;
Greene et al, 2002). Although the benefit of adjuvant chemother-
apy has clearly been demonstrated for stage III colon cancer, only
5–15% of these patients will benefit from this modality;
consequently, 85–95% of these patients undergoing adjuvant
chemotherapy will be overtreated (Mamounas et al, 1999).
Therefore, novel markers that pretherapeutically identify stage
III patients likely benefiting from adjuvant approaches are
urgently needed.
Colon carcinogenesis has been shown to be a multi-step
process of both histo-morphological and molecular alterations.
Singular stages of neoplastic transformation are associated
with either the inactivation of tumour suppressor or the activation
of oncogenes (Fearon and Vogelstein, 1990). An alternative
pathway of tumorigenesis is characterised by a defective DNA
mismatch repair system and the rapid accumulation of
somatic mutations (Perucho, 1996). As a consequence, the
epithelial homeostasis is disrupted by an imbalance of apoptotic
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sand mitotic processes. While accelerated proliferation increases
the occurrence of genetically damaged cells, the inhibition
of apoptosis is believed to confer a growth advantage and
to prevent the elimination of genetically altered cells. Both
mechanisms are thought to contribute to the initiation
and progression of malignancies (Kerr et al, 1972; Williams and
Smith, 1993).
In the search for better prognostic information, genes or
proteins involved in these processes represent natural candidate
markers, and genetic alterations in either tumour suppressor
or oncogenes have been reported to be associated with a
worse prognosis in colon cancer. However, in regard to the
prognostic information on the majority of suggested candidate
markers, results have been controversial and so far no molecular
alteration has changed clinical practice outside research
programmes.
The Bcl-2 family of proteins is intimately involved in the
regulation of apoptosis. While Bcl-2 and Bcl-x represent important
inhibitors of apoptosis, the BAX subfamily consisting of BAX, Bak
as well as the BH3-only subfamily induces programmed cell death
(Yang and Korsmeyer, 1996; Reed, 1997, 1998). This is also true for
apoptosis induced by cytotoxic treatment (Wagener et al, 1996).
Among the members of the Bcl-2 family, BAX is suggested to be a
key regulator of the apoptotic machinery, transcriptionally
activated by upstream molecules, such as the tumour suppressor
p53 (Miyashita and Reed, 1995). However, BAX-induced apoptosis
through p53-independent mechanisms in response to anticancer
agents has been found in colorectal cell line studies as well (Ravi
and Bedi, 2002).
On the other hand, it was proposed that the regulation of the
cellular suicide programme in response to cellular stress depends
on the dynamic interaction between Bcl-2 and BAX. Thus, higher
relative BAX levels might result in apoptotic cell death, whereas
higher relative Bcl-2 levels might inhibit this programme in
response to genotoxic stress (Oltvai et al, 1994). The prognostic
information of BAX protein expression has been tested for a
variety of malignancies, and a recent study reported a significant
worse prognosis of those patients with colorectal cancer whose
liver metastasis showed low proapoptotic BAX expression (Sturm
et al, 1999). However, data regarding the prognostic value of Bcl-2
or p53 expression in colorectal cancer are contradictory, as
recently reviewed by our group and others (Grizzle et al, 2002;
Klump et al, 2004).
In stage III colorectal carcinoma, patients with high-frequency
microsatellite instability (MSIþ) lesions have been shown to
display a different prognosis than those with microsatellite-
competent or low-frequency microsatellite instability (MSI )
neoplasms. Recent evidence suggests that stage III patients whose
tumours are categorised as MSIþ may not benefit from 5-
fluorouracil (5-FU)-based adjuvant treatment (Ribic et al, 2003),
whereas others have found contradictory results (Elsaleh et al,
2001). BAT26, a mononucleotide microsatellite marker, has been
demonstrated to be sufficient to screen for high-frequency MSI in
colorectal cancer of Caucasian populations with a sensitivity of
97% and more (Hoang et al, 1997; Zhou et al, 1998; Loukola et al,
2001).
Possibly, evaluation of the interplay between different mediators
instead of performing monogenic studies may help to provide
more reliable molecular information to predict clinical outcome in
colorectal cancer.
Accordingly, this study sought to further identify the predictive
and/or prognostic significance of BAX, Bcl-2 and p53 expression
and BAT26 alone, as well as the role of BAX combined with
Bcl-2 or p53 or BAT26 in UICC stage III colon cancer. Since
adjuvant chemotherapy represents the standard of care in stage III
colon carcinoma, the influence of the above-mentioned markers
on the outcome of adjuvant 5-FU-based chemotherapy was to be
tested.
MATERIALS AND METHODS
Patients and materials
A total of 188 patients with histologically confirmed diagnosis of
stage III colon cancer (UICC) were included. All patients were
entered into the prospective study of the Study Group Gastro-
intestinal Oncology North-Rhine Westphalia between December
1991 and December 1994. In this clinical trial, a total of 680 eligible
patients were randomly assigned to receive potentially curative
surgical resection followed by adjuvant chemotherapy with 5-FU
combined with leucovorin (arm A) or levamisole (arm B) as
previously described (Porschen et al, 2001; Arkenau et al, 2003).
As it was not an obligate requirement of the protocol to send the
tissue samples, archival resected specimens were available from
only 204 patients. Of these, 15 patients were excluded, one of them
owing to insufficient paraffin material and 14 patients because they
did not receive adjuvant chemotherapy at all. Analysis for MSI
status was performed on only 174 of the 188 samples because of
PCR failure due to insufficient tumour DNA.
The age of patients ranged from 34 to 80 years with a median age
of 62 years. We defined right-sided tumours as those arising
proximal to the splenic flexure, and left-sided as those originating
distal to Cannon’s point. The median follow-up was 84.5 months
(range 2.4–117.4 months). Further details of the study population
and tumour characteristics are given in Table 1A and B.
The German multicentric trial was approved by the Ethical
Committee of the Faculty of Medicine of the Heinrich-Heine-
University of Du ¨sseldorf.
Histopathology
After surgery, tumour specimens, resection margins and lymph
nodes were formalin fixed and paraffin embedded. Haematoxylin-
and eosin-stained sections were reviewed to establish the
pathological diagnosis and stage according to the tumour node
metastasis classification of the UICC (Sobin and Wittekind, 1997)
and the World Health Organization grading system (Jass and
Sobin, 1989) (FB, MS).
Clinical follow-up
Follow-up was performed in accordance with a standardised
scheme established within the clinical trial’s protocol (Arkenau
et al, 2003). Follow-up forms were sent to participating centres
for each patient on a quarterly basis for the first 2 years, on a
semiannual basis for the next 3 years and yearly thereafter.
Examinations included history, physical examination, blood tests,
CEA determinations (optionally) and abdominal ultrasound every
3 months during the first 2 years and every 6 months thereafter.
Colonoscopy and chest radiography were recommended every 6
months during the first 2 postoperative years and then once per
year. Abdominal computed tomography was performed 3 months
after surgery and repeated every 12 months.
Patients and treating physicians were alerted before the follow-
up date to improve compliance. Patients were classified as having
no evidence of disease or having evidence of relapse. Relapse was
defined as local recurrence, the manifestation of a secondary
metachronous tumour or development of distant metastasis.
Immunohistochemistry
Paraffin sections (5mm) were deparaffinised and rehydrated
through graded alcohols. Endogenous peroxidase activity was
blocked by incubation with 0.3% hydrogen peroxide for 10min.
Antigen retrieval was performed by fractioned (3 5min) micro-
wave treatment in citrate buffer (pH 6.0). Subsequently, sections
were covered for 30min at room temperature with normal horse
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sserum (for p53), normal swine serum (for BAX) and normal cow
serum (for Bcl-2) to block nonspecific background staining before
incubation with primary antibodies. Primary antibodies were
the monoclonal antibody DO-1 for p53 (Oncogene Science,
Cambridge, MA, USA; dilution 1:50 for 1h), the rabbit
anti-human antibody for BAX (N20, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA; dilution 1:200 for 1h30) and the mouse
anti-human monoclonal antibody for Bcl-2 (Dako Diagnostika,
Table 1A Clinicopathological parameters in relation to p53, BAX and Bcl-2 protein expression (n¼188)
BSI (no. (%)) Bcl-2 (no. (%)) p53 (no. (%))
n High Low P High Low P Positive Negative P
Sex
Male 79 44 (55.7) 35 (44.3) 0.43 52 (65.8) 27 (44.2) 0.33 42 (53.2) 37 (46.8) 0.46
Female 109 67 (61.5) 42 (38.5) 79 (72.5) 30 (27.5) 52 (47.7) 57 (52.3)
Age, years
p62 98 63 (64.3) 35 (35.7) 0.13 68 (69.4) 30 (30.6) 0.93 52 (53.1) 46 (46.9) 0.38
462 90 48 (53.3) 42 (46.7) 63 (70.0) 27 (30.0) 42 (46.7) 48 (53.3)
T category, pathologic
T2 19 11 (57.9) 8 (42.1) 0.92 15 (78.9) 4 (21.1) 0.35 10 (52.6) 9 (47.4) 0.81
T3–4 169 100 (59.2) 69 (40.8) 116 (68.6) 53 (31.4) 84 (49.7) 85 (50.3)
N category, pathologic
N1 107 67 (62.6) 40 (37.4) 0.25 75 (70.1) 32 (29.9) 0.89 49 (45.8) 58 (54.2) 0.19
N2–3 81 44 (54.3) 37 (45.7) 56 (69.1) 25 (30.9) 45 (55.6) 36 (44.4)
Differentiation
G1–2 138 89 (64.5) 49 (35.5) 0.01 97 (70.3) 41 (29.7) 0.76 69 (50.0) 69 (50.0) 1
G3–4 50 22 (44.0) 28 (56.0) 34 (68.0) 16 (32.0) 25 (50.0) 25 (50.0)
Location
Right 93 51 (54.8) 42 (45.2) 0.25 58 (62.4) 35 (37.6) 0.03 43 (46.2) 50 (53.8) 0.31
Left 95 60 (63.2) 35 (36.8) 73 (76.8) 22 (23.2) 51 (53.7) 44 (46.3)
Treatment arm
Arm A (5-FU/LV) 95 56 (58.9) 39 (41.1) 0.98 69 (72.6) 26 (27.4) 0.37 44 (46.3) 51 (53.7) 0.31
Arm B (5-FU/LEV) 93 55 (59.1) 38 (40.9) 62 (66.7) 31 (33.3) 50 (53.8) 43 (46.2)
G1, well; G2, moderately; G3, poorly; G4, anaplastic. Bold values signify Po0.05.
Table 1B Clinicopathological parameters in relation to microsatellite status (n¼174)
n MSI  (no. (%)) MSI+ (no. (%)) P
Sex
Male 76 71 (93) 5 (7) 0.29
Female 98 87 (89) 11 (11)
Age, years
p62 93 88 (95) 5 (5) 0.06
4 62 81 70 (86) 11 (14)
T category, pathologic
T2 18 18 (100) 0 (0) 0.38
T3–4 156 140 (90) 16 (10)
N category, pathologic
N1 99 92 (93) 7 (7) 0.27
N2–3 75 66 (88) 9 (12)
Differentiation
G1–2 125 115 (92) 10 (8) 0.38
G3–4 49 43 (88) 6 (12)
Location
Right 87 71 (82) 16 (18) o0.0001
Left 87 87 (100) 0 (0)
Treatment arm
Arm A (5-FU/LV) 90 84 (93) 6 (7) 0.23
Arm B (5-FU/LEV) 84 74 (88) 10 (12)
G1, well; G2, moderately; G3, poorly; G4, anaplastic. Bold values signify Po0.05.
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sHamburg, Germany; dilution 1:30 overnight). Slides were
incubated with diluted primary antibodies for p53 and BAX at
room temperature, whereas incubation for Bcl-2 was performed
at 41C. Subsequently, slides were covered with appropriate
biotinylated secondary antibody at room temperature and an
avidin-biotinylated peroxidase complex (Vectastain ABC Kit,
Vector Labs, Burlingame, CA, USA) for 30min each. Sections
were then developed using 3,30-diaminobenzidine and counter-
stained with haemalaun solution and mounted using aqueous
medium. Slides were washed twice between incubations with Tris-
buffered saline (pH 7.4). For each antibody, a known positive
colon cancer specimen served as positive control. Negative control
slides were processed with each slide run excluding the primary
antibody but with inclusion of all other steps of the procedure.
Randomly repeated slide runs showed the same staining proper-
ties, depicting the consistency of the staining.
Quantification of immunostaining
Expression patterns were independently determined by two
investigators in a semiquantitative manner by light microscopy
considering whole tumour specimen slides blind to clinicopatho-
logical variables and outcome, respectively. In case of discrepant
results, a final consensual decision was made.
Immunoreactivity for p53 (nuclear staining) and Bcl-2 (cyto-
plasmic staining) was categorised in accordance with the
percentage of tumour cells stained as described previously:
immunonegative, p5%; immunopositive, 45% staining.
BAX staining index (BSI) was established based on information
on both staining intensity and the percentage of positive cells
within a tumour. Five categories were defined for the percentage
of positive cells (1, 0%; 2, 40–60%; 3, 460–80%; 4, 480–99%;
and 5, 100%). Four categories were defined for staining intensity
(1, not detectable; 2, weak; 3, moderate; and 4, strong). The BSI was
defined as the product of score points found for both intensity and
percentage of positive cells (i.e. 1–20 points achievable). For
further univariate and multivariate analyses, samples were
dichotomised according to the median BSI value slightly modified
as described previously (Nehls et al, 2005) as follows: low BAX
expression, BSI o12, and high BAX expression, BSIX12.
Molecular analysis
For MSI analysis, tumour DNA was extracted from formalin-fixed
paraffin-embedded surgical resection specimens. Regions with
invasive cancer were identified on a reference H&E-stained sample
and then microdissected with a surgical scalpel blade. The
specimen was deparaffinised and then the extracted DNA was
amplified by PCR with the use of the BAT26 mononucleotide
microsatellite marker as described by Hoang et al (1997). BAT26-
amplified PCR products were run on nondenaturing polyacryla-
mide gels and stained with ethidium bromide. Samples were
dichotomised into presence (MSIþ) or absence of MSI (MSI )
including low-frequency MSI cases or microsatellite stable lesions.
Statistical analysis
The association of immunoreactivity and other established or
suggested factors of prognostic impact in colon cancer (i.e. age,
sex, pT category, pN category, tumour differentiation, tumour
localisation and treatment arm) was analysed as dichotomised
variables using the w
2 test. Primary statistical outcomes were
disease-specific overall survival and disease-free survival (OS/DFS)
measured from the date of surgery; OS and DFS were estimated by
Kaplan–Meier curves and curves were compared by means of the
log-rank test. Time to relapse and to death were analysed using the
Cox proportional hazards model for univariate and multivariate
analysis in a stepwise manner. Potential prognostic factors were
entered into a stepwise regression model from which significance
levels were determined. In addition, the hazard ratios between
prognostic groups and their 95% confidence intervals were
computed. Statistical significance was defined as a two-sided
Po0.05. Statistical analysis was performed using the SPSS
statistical software program (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical course of patients
Median duration of follow-up after surgery was 84.5 months or 6.6
years, with a range of 2.4–117.4 months. A relapse was diagnosed
in 38.3% of patients. Five-year survival was 69.9%.
Immunohistochemistry
Cytoplasmic BSI was classified as high (Figure 1A) and low in 111
(59%) and 77 (41%) tumours, respectively. Cytoplasmic Bcl-2
expression was positive (Figure 1B) and negative in 131 (70%) and
57 (30%) samples, and nuclear p53 immunoreactivity was
categorised in 94 (50%) tumours as positive (Figure 1C) and
negative, respectively.
In seven specimens (3.7%), no staining of BAX was detectable.
Any immunoreactivity for BAX was quantitatively detected in 181
(96.3%) tumour specimens: in 15 (8%) between 1 and 60% of cells,
in 33 (17.6%) between 61 and 80%, in 39 (20.7%) between 81 and
99%, and in 94 (50%) in all positive stained cells. Qualitatively,
BAX staining intensity was weak in 52 (27.7%) of the samples,
moderate in 72 (38.3%) and strong in 57 (30.3%).
Bcl-2 was detected in 57 (30%) of the samples in 5% of cells or
less, in 34 (18%) between 45 and 20%, in 11 (6%) between 420
and 50%, and in 86 (46%) in more than 50%.
p53 was found in 94 (50%) of the tumours in 5% of cells or less,
in 25 (13%) in 45–25%, in 3 (2%) between 425 and 50%, and in
66 (35%) in more than 50%.
BAX, Bcl-2 and p53 immunostainings were strong in all normal
colon tissue samples, which served as controls.
Molecular analysis
Of the 174 evaluable tumour specimens tested for MSI status, 16
(9%) demonstrated MSIþ and 158 tumours (91%) were cate-
gorised as MSI .
Univariate analysis of clinicopathological and genetic
correlations
By univariate analyses, BAX (BSI), Bcl-2 and p53 immunostainings
were compared with treatment arm and various tumour char-
acteristics (sex, age, pT category, pN category, grade of
differentiation (G category) or localisation). In contrast to other
tumour parameters and treatment arm, a significant association of
G category and BSI was detected with tumours of lower
differentiation showing a decreased level of BAX protein expres-
sion (P¼0.01). Furthermore, a significant correlation of tumour
location and Bcl-2 expression or the MSI phenotype was found
with left-sided tumours revealing higher Bcl-2 expression levels
(P¼0.03) or with right-sided neoplasms showing an association
with MSIþ cases (Po0.0001) (Table 1A and B).
High BSI was positively correlated to Bcl-2 immunopositivity
(P¼0.002; w
2 test), whereas no significant association was found
among p53 and BSI or Bcl-2 (P¼0.5 and P¼0.9, respectively; w
2
test). Moreover, presence of MSIþ lesions was correlated both
with low Bcl-2 expression levels (P¼0.02; w
2 test) and with p53
immunonegativity (P¼0.04; w
2 test), whereas no significant
association was found among MSI status and BSI (P¼0.2; w
2 test).
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sUnivariate analysis for survival
BAX expression revealed a significant impact on both DFS
(Figure 2A; Kaplan–Meier curves for DFS) and OS (Figure 3A;
Kaplan–Meier curves for OS), whereas the expression levels of
neither Bcl-2 nor p53 or the MSI status were statistically
significantly related to DFS or OS. Thus, 5-year DFS or OS in
tumours with low and high BSI were 48.2 and 71.7%, respectively
(P¼0.0005, log-rank test), or 60.7 and 76.1%, respectively
(P¼0.002, log-rank test), whereas 5-year DFS or OS in patients
with positive and negative Bcl-2 levels were 59.9 and 67.3%,
respectively (P¼0.7), or 69.3 and 71.3%, respectively (P¼0.7).
Similarly, 5-year DFS or OS in p53-positive and -negative cases
were 57.0 and 67.3%, respectively (P¼0.2), or 67.3 and 72.6%,
respectively (P¼0.2). Likewise, 5-year DFS or OS in MSI  and
MSIþ individuals were 59.4 and 67.5%, respectively (P¼0.51), or
68 and 81.3%, respectively (P¼0.42).
The clinicopathological variables significantly associated with
DFS and OS were lymph node category comparing pN1 with pN2-3
(5-year DFS 71.6 vs 49.3%; P¼0.001; 5-year OS 80.2 vs 55.7%,
P¼0.0001), grade of differentiation when subdivided into G1/2 vs
G3/4 (5-year DFS 66.8 vs 49.3%; P¼0.005; 5-year OS 74.9 vs 55.6%,
P¼0.003) and treatment arm comparing arm A with arm B (5-year
DFS 70.5 vs 53.2%; P¼0.01; 5-year OS 76.7 vs 60.7%, P¼0.02),
whereas T category when subdivided into pT1/2 vs pT3/4 was only
of borderline significance in correlation to DFS (5-year DFS 83.9 vs
59.7%, P¼0.05).
Other clinicopathological parameters like age, sex and tumour
site were not statistically significantly associated with DFS or OS
(Table 2).
Figure 1 Light microscope images ( 40) of immunohistochemistry of representative colon cancer samples classified as BSI high (BAX was quantitatively
detected in all positive stained cells and BAX staining intensity was classified as strong) (A), Bcl-2 immunopositive (45% cytoplasmic staining) (B) and p53
immunopositive (45% nuclear staining) (C).
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Figure 2 Kaplan–Meier DFS analysis for BAX (BSI) alone (A), for the p53/BAX high phenotype, subdivided into its two subtypes (p53 /BSI high or
p53þ/BSI high) (B), or for the MSI/BSI phenotype, subdivided into its two subtypes (MSI /BSI high or MSIþ/BSI high) (C).
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the BAX/MSI  phenotype
In view of the combined BAX/Bcl-2 phenotype with its four
subtypes, 24 cases were BSI high/Bcl-2 , 87 were BSI high/Bcl-2þ,
33 were BSI low/Bcl-2  and 44 were BSI low/Bcl-2þ. The subset of
BSI high/Bcl-2  cases was associated with the best prognosis (5-
year DFS 82.6%; 5-year OS 87.1%); among patients with the BSI
high/Bcl-2þ phenotype, outcome was associated with an inter-
mediate prognosis (5-year DFS 68.8%; 5-year OS 73.1%) (Table 3),
whereas patients harbouring the BSI low/Bcl-2  or þ phenotype
were found to have the worst prognosis (5-year DFS 56.8 or 41.4%;
5-year OS 61.4 or 59.5%) (Figure 4). Comparing patients with the
BSI high/Bcl-2  or þ phenotype as well as those with BSI low/Bcl-
2  or þ lesions showed no significant differences regarding
5-year DFS or 5-year OS (Table 3 and Figure 4).
With respect to the four subtypes of the p53/BAX phenotype, 58
lesions were identified as p53 /BSI high, 53 were p53þ/BSI high,
36 were p53 /BSI low and 41 were p53þ/BSI low. Subjects
harbouring p53 /BSI high lesions exerted a favourable prognosis
as compared to p53 /BSI low or p53þ/BSI low cases (5-year DFS
80.7 vs 45.5 or 50.4%; 5-year OS 80.8 vs 58.5 or 62.6%), whereas
patients with the p53þ/BSI high phenotype were observed to have
an intermediate-risk profile (5-year DFS 61.9%; 5-year OS 70.9%).
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Figure 3 Kaplan–Meier OS analysis for BAX (BSI) alone (A), for the p53/BAX high phenotype, subdivided into its two subtypes (p53 /BSI high or
p53þ/BSI high) (B), or for the MSI/BSI phenotype, subdivided into its two subtypes (MSI /BSI high or MSIþ/BSI high) (C).
Table 2 Analysis of DFS and OS in relation to clinicopathological
parameters, p53, BAX and Bcl-2 protein expression and MSI status
n
5-year DFS
(%) P
5-year OS
(%) P
Sex
Male 79 57.1 0.2 68.8 0.3
Female 109 65.7 70.7
Age, years
p62 98 64.7 0.6 72.7 0.4
462 90 59.4 66.8
T category, pathologic
T2 19 83.9 0.05 83.9 0.1
T3–4 169 59.7 68.3
N category, pathologic
N1 107 71.6 0.001 80.2 0.0001
N2–3 81 49.3 55.7
Differentiation
G1–2 138 66.8 0.005 74.9 0.003
G3–4 50 49.3 55.6
Location
Right 93 66.9 0.1 74.2 0.3
Left 95 57.1 65.5
Treatment arm
Arm A (5-FU/LV) 95 70.5 0.01 76.7 0.02
Arm B (5-FU/LEV) 93 53.2 62.4
BAX staining index
High 111 71.7 0.0005 76.1 0.002
Low 77 48.2 60.7
Bcl-2 expression
Positive 131 59.9 0.7 69.3 0.7
Negative 57 67.5 71.3
p53 expression
Positive 94 57 0.2 67.3 0.2
Negative 94 67.3 72.6
MSI status
MSI  158 59.4 0.5 68 0.4
MSI+ 16 67.5 81.3
Kaplan–Meier curves compared by log-rank test. DFS¼disease-free survival;
MSI¼microsatellite instability; OS¼overall survival. Bold values signify Po0.05.
Table 3 Bivariate subgroup analysis of patients with high or low BSI
lesions combined with either Bcl-2 /+ or p53 /+ or MSI /+ samples in
relation to 5-year DFS and 5-year OS (log-rank test)
n 5-year DFS (%) P 5-year OS (%) P
BSI high/Bcl-2  24 82.6 0.2 87.1 0.2
BSI high/Bcl-2+ 87 68.8 73.1
BSI low/Bcl-2  33 56.8 0.7 59.5 0.7
BSI low/Bcl-2+ 44 41.4 61.4
BSI high/p53  58 80.7 0.03 80.8 0.07
BSI high/p53+ 53 61.9 70.9
BSI low/p53  36 45.5 0.7 58.5 0.8
BSI low/p53+ 41 50.4 62.6
BSI high/MSI  97 68.6 0.11 73.7 0.13
BSI high/MSI+ 7 100 100
BSI low/MSI  61 44.4 1 58.6 0.9
BSI low/MSI+ 9 55.6 66.7
BSI¼BAX staining index; DFS¼disease-free survival; 5-FU¼5-fluorouracil;
LEV¼levamisole; MSI¼microsatellite instability; OS¼overall survival. Bold values
signify Po0.05.
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with BSI high/p53þ lesions had an improved 5-year DFS
(P¼0.03) (Figure 2B; Kaplan–Meier curves for DFS) and a
marginally improved 5-year OS (P¼0.07) (Figure 3B; Kaplan–
Meier curves for OS), whereas no such difference was noted among
cases with BSI low/p53  or þ tumours (Table 3).
Among 174 tumour specimens for which the MSI status was
performed, the BSI high/MSI  phenotype was found in 97
samples, seven lesions were BSI high/MSIþ, 61 were BSI
low/MSI  and nine were BSI low/MSIþ. Five-year DFS or
OS in tumours with the BSI high/MSIþ phenotype were 100
and 100%, respectively, as compared with 68.6 or 73.7%,
respectively, among those with the BSI high/MSI  phenotype
(P¼0.11 or P¼0.13, respectively) (Figures 2C and 3C;
Kaplan–Meier curves for DFS and OS). Five-year DFS or OS rates
were 44.4 or 58.6% in the BSI low/MSI  group and 55.6 or 66.7%
in the BSI low/MSIþ group (P¼1.0 or P¼0.9, respectively)
(Table 3).
Multivariate analysis
Multivariate analysis using Cox proportional hazards regression
showed BAX expression to be a major independent prognostic
factor for both DFS (Table 4) and OS (Table 5) (P¼0.001 and
P¼0.003, respectively). Other independent negative predictive
factors for both DFS and OS were the presence of two or more
positive lymph nodes (P¼0.005 and Po0.0001, respectively) and
allocation to treatment arm B, respectively (P¼0.008 and P¼0.01,
respectively). Other clinicopathological variables like age, gender,
pT category and tumour location were not statistically significant
independent markers in terms of DFS (Table 4) or OS (Table 5).
Multivariate subgroup analysis including only subjects with BSI
high tumours (n¼111) and considering factors as covariates
potentially to be correlated with disease recurrence and/or
mortality like p53 status, pT category, pN category and treatment
arm yielded p53 immunopositivity as the only independent marker
for improved DFS (P¼0.03), whereas it marginally failed to prove
to be of significance in terms of OS (P¼0.08). In this subset of
patients, advanced lymph node category was a negative prognos-
ticator of borderline significance for DFS and an independent
factor for OS (P¼0.066 and P¼0.03, respectively) (data not
shown).
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Figure 4 Kaplan–Meier OS analysis for the BAX/Bcl-2 group, subdivided
in its four subsets (BSI high/Bcl-2 , BSI high/Bcl-2 þ, BSI low/Bcl-2 , BSI
low/Bcl-2þ).
Table 4 Multivariate analysis of clinicopathological and genetic para-
meters for DFS (Cox regression hazard analysis)
DFS
Prognostic factor P-values Hazard ratio 95% CI
Step 1
pT category
T3/4 0.11 2.6 0.8–8.3
pN category
N2/3 0.008 1.9 1.2–3.1
Differentiation
G3/4 0.22 1.4 0.8–2.3
Treatment arm
Arm B (5-FU/LEV) 0.01 1.9 1.2–3.0
BSI
Low 0.001 2.2 1.4–3.6
Step 2
pT category
T3/T4 0.09 2.7 0.9–8.7
pN category
N2/3 0.005 2 1.2–3.2
BSI
Low 0.001 2.3 1.4–3.7
Treatment arm
Arm B (5-FU/LEV) 0.008 1.9 1.2–3.1
CI¼confidence interval; DFS¼disease-free survival; 5-FU¼5-fluorouracil;
LEV¼levamisole. Bold values signify Po0.05.
Table 5 Multivariate analysis of clinicopathological and genetic para-
meters for OS (Cox regression hazard analysis)
OS
Prognostic factor P-values Hazard ratio 95% CI
Step 1
pT category
T3/4 0.27 2 0.6–6.3
pN category
N2/3 0.001 2.3 1.4–3.8
Differentiation
G3/4 0.18 1.4 0.9–2.4
Treatment arm
Arm B (5-FU/LEV) 0.02 1.8 1.1–3.8
BSI
Low 0.004 2.1 1.3–3.4
Step 3
pN category
N2/3 o0.0001 2.5 1.5–4.2
BSI
Low 0.003 2.1 1.3–3.5
Treatment arm
Arm B (5-FU/LEV) 0.01 1.9 1.1–3.1
CI¼confidence interval; 5-FU¼5-fluorouracil; LEV¼levamisole; OS¼overall
survival. Bold values signify Po0.05.
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Recent reports by our group and others have suggested the
proapoptotic BAX protein to act as a tumour suppressor in human
malignancies (Zhan et al, 1994; Zhang et al, 2000; Schelwies et al,
2002; Klump et al, 2004) playing a key role in mediating the apo-
ptotic programme in response to genotoxic stress (Theodorakis
et al, 2002). For this reason, we examined, in a well-characterised,
homogeneous collective of patients, whether BAX has a prognostic
influence in stage III colon carcinoma treated by adjuvant
chemotherapy. Additionally, we considered the interaction be-
tween proapoptotic BAX and its antiapoptotic counterpart Bcl-2 as
well as its proposed transcriptional upstream regulator p53 in
these series of experiments. Based on the observed prognostic
value of these proteins by use of an immunohistochemical assay in
colorectal cancer by our group and others (Sinicrope et al, 1995;
Schelwies et al, 2002; Klump et al, 2004; Nehls et al, 2005), we
followed this approach in the current study as well. High-
frequency instability of microsatellites is present in about 15% of
the cases of sporadic colorectal carcinoma, and it appears to be
associated with different prognostic features as compared with
tumours harbouring microsatellite stable or low-frequency micro-
satellite unstable lesions. Therefore, we screened 174 samples with
enough DNA material for high-frequency MSI using the mono-
nucleotide microsatellite marker BAT26. This marker alone was
demonstrated to be sufficient to identify 97% of the MSIþ cases of
494 colorectal carcinoma samples (Loukola et al, 2001).
We found a high BSI or immunopositivity for Bcl-2 and p53 in
59, 70 and 50% of the cases, respectively. MSIþ lesions were
detected in 9% of 174 evaluable patients. The observation in the
present study that a high cytoplasmic BSI occurred with a lower
frequency as compared to our previous rectal cancer trial (59 vs
68.5%) may be attributed to a slightly modified scoring system in
our present series, in which we used the median BSI as cutoff value
as described previously (Schelwies et al, 2002). The percentage of
Bcl-2 and p53 immunopositivity (70 and 50%, respectively) is in
good accordance with the results of a non-metastatic colon cancer
study using both the same antibodies and the same scoring system
as we did, thereby detecting cytoplasmic Bcl-2 and nuclear p53
immunopositivity in 66 and 48% of 110 cases, respectively
(Sinicrope et al, 1995). The rate of MSIþ tumours observed in
our study is in accordance with the data of Elsaleh et al (2001),
who also found 9% MSIþ cases in a large series of stage III
colorectal carcinoma using BAT26. In line with a previous study on
colorectal cancer (Schelwies et al, 2002), we detected a reciprocal
correlation between BAX expression and grading.
The main findings of our work were that high BSI was highly
significantly associated with an improvement of both DFS and OS
by multivariate analysis in 188 stage III colon carcinoma patients
who had received cytotoxic therapy, whereas presence or absence
of Bcl-2 or p53 expression alone was significantly correlated with
clinical outcome.
Our data nicely confirm recent preclinical data showing that
BAX is of crucial significance for the induction of apoptosis by
5-FU in colon cancer cell lines (Theodorakis et al, 2002).
Moreover, a positive prognostic relevance of high BAX expression
in 41 colorectal cancer patients who underwent curatively intended
resection of liver metastases has been reported – since a
substantial proportion of these patients (71%) had received 5-
FU-based cytotoxic therapy after complete surgical resection of
their lesions, we feel that these data are in good concordance
with ours (Sturm et al, 1999). Furthermore, we reported in our
initial studies on 92 rectal cancer patients, all treated by
neoadjuvant radiotherapy concurrent to surgery, that a high BSI
was independently linked to an improved rate of disease
recurrence underlining the potential predictive value of BAX in
the setting of genotoxic therapy in colorectal cancer as well (Nehls
et al, 2005).
Although BAX may be a central effector of its proposed
transcriptional regulator, the tumour suppressor gene p53
(Miyashita and Reed, 1995), we found, consistent with the results
of others (Watanabe et al, 2001), no significant correlation
between p53 protein expression alone and outcome in our series.
However, according to another trial, p53 was found to predict
clinical outcome in colorectal cancer patients treated by adjuvant
5-FU-based treatment (Ahnen et al, 1998). Hypothetically, these
contradictory results may be explained by differential expressions
of BAX, which was supposed to act as a central downstream
effector of p53 (Miyashita and Reed, 1995). Accordingly, in the
present trial, subgroup analysis showed that patients with p53 /
BSI high tumours were less likely to experience relapse or death
than those harbouring p53þ/BSI high lesions (5-year DFS 80.7 vs
61.9 months, P¼0.03; 5-year OS 80.8 vs 70.9 months, P¼0.07,
respectively), suggesting a positive association between an intact
p53/BAX pathway and clinical outcome. Thus, the proapoptotic
effect of BAX, positively influencing clinical behaviour, may even
be more corroborated in patients with p53-immunonegative
lesions. A similar correlation was found in a recent report on
metastatic colorectal cancer demonstrating a clear survival
advantage for patients with an intact p53/BAX pathway (p53 wild
type/BAX high) as well (Sturm et al, 1999).
Therefore, BAX might constitute a critical element probably
mediating cell susceptibility to undergo apoptotic cell death, which
additionally might depend on the p53 expression status in the
context of genotoxic stress in colon cancer.
We also evaluated the prognostic role of antiapoptotic Bcl-2, the
so-called counteracting twin of BAX (Korsmeyer, 1999). However,
in contrast to BAX, Bcl-2 expression alone was not observed to
be prognostically useful in stage III colon cancer, which is in line
with previous reports on the prognostic significance of Bcl-2 in
adjuvantly treated non-metastatic colorectal cancer (Tollenaar
et al, 1998; Garrity et al, 2004). In addition, combined analysis of
the BAX/Bcl-2 phenotypes did not confer additional significant
prognostic information over BAX alone. Thus, a high BSI
combined with either negative or positive Bcl-2 levels was
associated with both improved DFS and OS as compared to
tumours that showed a low BSI combined with either Bcl-2-
negative or -positive samples. Nevertheless, in contrast to BSI low/
Bcl-2  or þ individuals showing essentially no difference for
long-term survival (5-year OS 61.4 vs 59.5%), patients with the BSI
high/Bcl-2  phenotype, as depicted in Figure 4, had an excellent
outcome that was moderately better as compared to BSI high/Bcl-
2þ cases (5-year OS 87.1 vs 73.1%), but the shift of the BAX to
Bcl-2 ratio in favour of the BSI high/Bcl-2  phenotype did not
translate into a statistically significant difference for clinical
outcome in our series of cytotoxically treated stage III colon
cancer (OS, P¼0.2). Consequently, the balance of the BAX to Bcl-2
ratio may in vivo functionally be predominated by the expression
status of BAX, which is consistent with the recent observation
that the proapoptotic activity of the multidomain protein BAX
might function independently of the Bcl-2 status (Knudson and
Korsmeyer, 1997). Furthermore, it has recently been demonstrated
that members of the Bcl-2 family other than Bcl-2 also may counter
BAX by forming heterodimers, thereby inhibiting the apoptotic
programme (Sedlak et al, 1995). Thus, Bcl-2 expression possibly
may not be of central prognostic significance in cytotoxically
treated stage III colon carcinoma.
Our observation that patients with MSIþ tumours did not have
a statistically significant better outcome as compared to those with
MSI  neoplasms is in line with the recent results of Ribic et al
(2003), demonstrating that patients who received adjuvant
5-FU-based chemotherapy and with MSIþ lesions had no better
outcome than those with MSI  neoplasms. However, others found
a significant survival benefit in MSIþ cases who received adjuvant
5-FU-based chemotherapy (Elsaleh et al, 2001). These conflicting
results may be explained by preclinical studies demonstrating that
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MSI  lesions (Carethers et al, 1999), which has been attributed to
the observation that mismatch repair proteins may be essential
to incorporate 5-FU into tumour DNA (Tajima et al, 2004),
whereas others found that MSIþ tumours may harbour an
intrinsic favourable prognosis (Popat et al, 2005).
Notably, bivariate subgroup analysis showed a nonsignificant
trend for survival benefit for patients with the BSI high/MSIþ
phenotype as compared to those with the BSI high/MSI 
phenotype. Furthermore, in all patients with the BSI high/MSIþ
phenotype, neither was there recurrence of disease nor any
disease-related death. Possibly, this subgroup of patients may
harbour an inherent favourable prognosis. However, these
observations should be interpreted with caution, given that only
nine patients had BSI high/MSIþ lesions. Therefore, prospective
studies on larger series may address this issue.
In conclusion, this study for the first time indicates a positive
predictive role of high BSI in the outcome of adjuvant
chemotherapy in stage III colon cancer. Thus, preclinical data
showing BAX expression to be of vital impact for 5-FU-induced
apoptosis in colon cancer cell lines are supported by the data
presented here. However, monogenic analysis of both the proposed
upstream regulator of BAX, p53, and its antiapoptotic relative,
Bcl-2, did not provide additional prognostic information either,
whereas bivariate analysis of the p53/BAX phenotype and the BSI
high/MSIþ phenotype possibly may add further prognostic
evidence.
Accordingly, it might be speculated that BAX enhances
chemotherapy-induced apoptosis by a pathway that does not
depend fundamentally on the BAX to Bcl-2 balance, but may be
influenced by intact p53 or by the MSI status. Therefore,
prospective studies evaluating whether the status of BAX protein
alone or in combination with p53 or MSI may contribute to the
identification of stage III patients who are benefited from adjuvant
chemotherapy are strongly suggested by these data.
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